Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.

3d illustration of T cells attacking a cancer cell
Manufacturing is key to Kite's cell therapy success, CEO Shaw says

Kite Pharma, Inc. CEO Christi Shaw is optimistic about Gilead Sciences, Inc.maintaining a leadership position in cancer cell therapy, especially as its second CAR-T therapy Tecartus appears poised for expansion in B-cell acute lymphoblastic leukemia. In an interview with Scrip, Shaw highlighted data recently presented at the American Society of Clinical Oncology annual meeting as evidence of the Kite subsidiary's expansion and commitment to cell therapy.

The company’s announcement of an alliance with Shoreline Biosciences, Inc. on 18 June, after the interview, on chimeric antigen...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.